



An Illustrated Guide to Meeting the Challenges of Treating Hemophilia

References

1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia*. 2020;26 Suppl 6:1-158.
2. Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. *Blood Adv*. 2020;4(11):2451-2459.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med*. 2007;357(6):535-544.
4. Monroe DM, Hoffman M. What does it take to make the perfect clot? *Arterioscler Thromb Vasc Biol*. 2006;26(1):41-48.
5. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. *Blood*. 2016;128(16):2007-2016.
6. Mannucci PM. Hemophilia therapy: the future has begun. *Haematologica*. 2020;105(3):545-553.
7. Graf L. Extended Half-Life Factor VIII and Factor IX Preparations. *Transfus Med Hemother*. 2018;45(2):86-91.
8. Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. *Haemophilia*. 2017;23(5):697-704.
9. Al-Salama ZT, Scott LJ. Lonoctocog alfa: A review in haemophilia A. *Drugs*. 2017;77(15):1677-1686.
10. Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. *N Engl J Med*. 2020;383(11):1018-1027.
11. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. *Nat Med*. 2012;18(10):1570-1574.
12. Samuelson Bannow B, Recht M, Negrier C, et al. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. *Blood Rev*. 2019;35:43-50.
13. Callaghan MU, et al. Abstract 1800. Presented at ASH Annual Meeting, 5th – 8th December 2020.
14. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. *Blood*. 2021;137(16):2231-2242.
15. MASAC Document 268 - Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors (4/2022). Available at <https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-258-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors>.
16. Mast AE. Tissue factor pathway inhibitor: Multiple anticoagulant activities for a single protein. *Arterioscler Thromb Vasc Biol*. 2016;36(1):9-14.
17. Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. *Blood*. 2019;134(22):1973-1982.
18. Mahlangu JN. Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management. *Front Med (Lausanne)*. 2021;8:670526.
19. Mahlangu J, Lamas JL, Morales JC, et al. Long-term safety and efficacy of the anti-TFPI monoclonal antibody marstacimab in patients with severe haemophilia A or B: Results from a phase 2 long-term treatment study. Abstract 268. *Res Pract Thromb Haemost*. 2021 Oct; 5(Suppl 2): e12591. <https://abstracts.isth.org/abstract/long-term-safety-and-efficacy-of-the-anti-tfpi-monoclonal-antibody-marstacimab-in-patients-with-severe-haemophilia-a-or-b-results-from-a-phase-2-long-term-treatment-study>

20. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (explorer7). Available at <https://clinicaltrials.gov/ct2/show/NCT04083781>.
21. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Available at <https://clinicaltrials.gov/ct2/show/NCT04082429>.
22. Novo Nordisk resumes the phase 3 clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors [press release]. Bagsværd, Denmark: Novo Nordisk; 13 August. Available at <https://ml-eu.globenewswire.com/Resource/Download/32302d78-439f-4a97-a655-3f7b96e2cc76#:~:text=Novo%20Nordisk%20has%20together%20with,safely%20restart%20the%20explorer%20trials>.
23. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. *Arterioscler Thromb Vasc Biol.* 2005;25(7):1311-1320.
24. Centessa Pharmaceuticals announces positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B patients not on prophylaxis [press release]. Cambridge, Mass. and London: Globe Newswire; Sept. 09, 2021. Available at <https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-positive-topline-data-proof>.
25. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. *Drugs.* 2007;67(10):1429-1440.
26. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI). Available at <https://ash.confex.com/ash/2021/webprogram/Paper150273.html>.
27. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: First results from a phase 3 study to evaluate efficacy and safety in people with hemophilia a or B *without* inhibitors (ATLAS-A/B). *Blood.* 2021;138(Supplement 2):LBA-3-LBA-3.
28. Trincherro A, Sholzberg M, Matino D. The evolution of hemophilia care: Clinical and laboratory advances, opportunities, and challenges. *Hamostaseologie.* 2020;40(3):311-321.
29. Lisowski L, Staber JM, Wright JF, Valentino LA. The intersection of vector biology, gene therapy, and hemophilia. *Res Pract Thromb Haemost.* 2021;5(6):e12586.
30. Rodriguez-Merchan EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: Recent advances. *Int J Mol Sci.* 2021;22(14):7647.
31. Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. *Expert Opin Biol Ther.* 2022;6:1-17.
32. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. *Lancet.* 2021;397(10274):630-640.
33. Nidetz NF, McGee MC, Tse LV, et al. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. *Pharmacol Ther.* 2020;207:107453.
34. Kattenhorn LM, Tipper CH, Stoica L, et al. Adeno-associated virus gene therapy for liver disease. *Hum Gene Ther.* 2016;27(12):947-961.
35. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. *Blood.* 2010;116(26):5842-5848.
36. Batty P, Lillcrap D. Hemophilia gene therapy: Approaching the first licensed product. *Hemasphere.* 2021;5(3):e540.
37. Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. *N Engl J Med.* 2022;386(11):1013-1025.
38. Ozelo CM, Mahlangu J, Pasi K, et al. Efficacy and safety of valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from the phase 3 GENER8-1 trial [abstract]. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 2). <https://abstracts.isth.org/abstract/efficacy-and-safety-of-valoctocogene-roxaparvovec-adeno-associated-virus-gene-transfer-for-severe-hemophilia-a-results-from-the-phase-3-gener8-1-trial/>. Accessed May 8, 2022.

39. BioMarin announces stable and durable annualized bleed control in the largest phase 3 gene therapy study in adults with severe hemophilia A; 134-participant study met all primary and secondary efficacy endpoints at two year analysis [press release]. San Rafael, Calif: PR Newswire; January 9, 2022. Available at <https://www.prnewswire.com/news-releases/biomarin-announces-stable-and-durable-annualized-bleed-control-in-the-largest-phase-3-gene-therapy-study-in-adults-with-severe-hemophilia-a-134-participant-study-met-all-primary-and-secondary-efficacy-endpoints-at-two-year-analysis-301456772.html>. Accessed May 9, 2022.
40. George LA, Monahan PE, Eyster ME, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. *N Engl J Med*. 2021;385(21):1961-1973.
41. Pfizer and Sangamo announce updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years following hemophilia A gene therapy [press release]. New York, NY, and Brisbane, California: Pfizer, Inc; December 12, 2021. Available at <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-1>. Accessed May 5, 2022.
42. Visweshwar N, Harrington TJ, Leavitt AD, et al. Updated results of the Alta Study, a phase 1/2 study of giroctocogene fitelparvovec (PF-07055480/SB-525) gene therapy in adults with severe hemophilia A. Abstract presented at American Society of Hematology Annual Meeting, December 12, 2021.
43. Figueiredo M. Gene therapy SB-525 controls bleedings in men for at least 2 years. *Hemophilia News Today*. December 20, 2021. Available at <https://hemophilianewstoday.com/2021/12/20/gene-therapy-sb-525-controls-hemophilia-a-related-bleedings-at-least-2-years>. Accessed May 5, 2022.
44. FDA places the Pfizer/Sangamo Therapeutics phase 3 AFFINE haemophilia A gene therapy study on clinical hold. National Hemophilia Foundation. Available at <https://www.hemophilia.org/news/fda-places-the-pfizersangamo-therapeutics-phase-3-affine-haemophilia-a-gene-therapy-study-on-clinical-hold>. Accessed May 3, 2022.
45. uniQure and CSL Behring announce primary endpoint achieved in HOPE-B pivotal trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B [press release]. Lexington, MA and Amsterdam, the Netherlands, King of Prussia, PA: CSL Behring; December 9, 2021. Available at <https://www.cslbehring.com/newsroom/2021/hope-b-gene-therapy-for-hemophilia-b-topline-results>. Accessed May 6, 2022. .
46. Samelson-Jones BJ, Sullivan SK, Rasko JEJ, et al. Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy. *Blood*. 2021;138(Supplement 1):3975-3975.